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group (32 patients) and placebo group (34 patients). Baseline clinical,
angiographic and periprocedural characteristics were not signiﬁcantly
different between the atorvastatin and control group except for age
and length of stent used, but they didn’t inﬂuence the IMR value.
There were no signiﬁcant differences in regard of fractional ﬂow
reserve (FFR) (0.94 vs. 0.96, p ¼ 0.39), coronary ﬂow reserve (CFR) (1.1
vs. 1.2, p ¼ 0.09) and also IMR (41.54[12.8-198.2] vs. 41.60 [10.4 –
200.3], p ¼ 0.61) between both groups.
CONCLUSION Administration of high loading dose of atorvastatin (80
mg) before primary PCI in STEMI patients didn’t improve microvas-
cular perfusion as measured by index of microvascular resistance
compare to placebo.ADJUNCTIVE PROCEDURES: THROMBECTOMY,
PLAQUE MODIFICATION, OTHERS (TCTAP A-021)
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BACKGROUND Treatment of calciﬁed lesions with balloon angioplasty
has been associated with a low success rate and high procedural
complications. Rotational atherectomy (RA) improved acute results,
but a high restenosis rate remained a problem. Therefore, the purpose
of this study was to evaluate the clinical and angiographic outcome of
patients with complex and calciﬁed lesions treated with a combination
of RA and second-generation drug-eluting stent (DES) implantation.
METHODS Consecutive 55 patients received combination therapy of
RA and second-generation DES implantation at de novo lesion of
native coronary artery with severe calciﬁcation between June 2009
and December 2012. Zotarolimus-eluting stents (ZES), biolimus-
eluting stent (BES), and everolimus-eluting stents (EES) were used in
14, 7, and 34 patients, respectively. 39 patients (ZES, BES, and EES
were used in 12, 6, 21 patients) received one-year follow-up angiog-
raphy. The clinical and angiographic outcome was compared among
those 3 groups of different DES.
RESULTS Only one patient was dead (a cause was unknown). Target
lesion revascularization (TLR) rate was 0% among 3 groups. The late
loss was larger in ZES than in BES or EES (ZES vs. BES vs. EES:
0.370.20mm vs. 0.200.10mm vs. 0.160.15mm, p<0.05).
CONCLUSION The clinical outcome of 3second-generation DES used
in combination with RA was very good, although the culprit lesions
were complex with severe calciﬁcation. Combination therapy of RA
and second-generation DES appeared acceptable.ANTIPLATELET AGENTS AND ANTICOAGULANTS
(TCTAP A-022 TO TCTAP A-025, TCTAP A-136)
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BACKGROUND It has been well known that new P2Y12 receptor
inhibitors (RI; prasugrel or ticagrelor) could improve clinical out-
comes in patients with acute myocardial infarction (AMI). However,there were little data about the impact of new P2Y12 RI in Korean
patients with AMI. Therefore, we compared the short-term clinical
outcomes between new P2Y12 RI and clopidogrel in patients with
AMI undergoing successful percutaneous coronary intervention
(PCI).
METHODS Between November 2011 and August 2014, a total of 4,029
patients (3,186 patients were prescribed clopidogrel and 843 patients
new P2Y12 RI [474 patients prasugrel and 369 patients ticagrelor])
with AMI undergoing successful PCI were included from Korea Acute
Myocardial Infarction Registry-National Institute of Health. The pa-
tients older than 75 years, weight< 60 kg, or with a history of stroke
and with in-hospital switching among 3 antiplatelet agents were
excluded. The propensity score matching (802 pairs) were performed
in order to compare the in-hospital clinical outcomes between new
P2Y12 RI and clopidogrel after adjusting for baseline clinical and
procedural confounders.
RESULTS P2Y12 reactivity unit by the Verify Now P2Y12 test was
77.574.50 in new P2Y21 RI and 212.280.72 in clopidogrel. The in-
cidences of Thrombolysis In Myocardial Infarction (TIMI) major
bleeding and minor bleeding were signiﬁcantly higher in new P2Y12
RI than clopidogrel (3.1% vs. 1.1%,p¼0.006; 4.1% vs. 1.9%, p¼0.008).
However, there were no signiﬁcant differences in in-hospital mor-
tality and the composite of cardiac death, MI or stroke during hospital
stay between new P2Y12 RI and clopidogrel (1.0% vs. 0.7%, p¼0.591;
1.0%vs. 1.1%, p¼0.807). Also, no difference in the composite of car-
diac death, MI, stent thrombosis, target vessel revascularization or
stroke at 6 months was observed in both group (1.0% vs. 2.3%,
p¼0.114). On multivariate analysis, use of statin, TFI vs. TRI and use
of glycoprotein IIb/IIIa inhibitors were independent predictors of the
composite of cardiac death, MI, stent thrombosis, stroke or TIMI
major bleeding (odd ratio [OR]¼0.187; 95% conﬁdence interval
[CI]¼0.083-0.422, OR¼10.811; 95%CI¼2.560-45.652,OR¼2.174; 95%
CI¼1.103-4.284).
CONCLUSION Our study shows that new P2Y12 RI had similar efﬁcacy
for preventing ischemic events compared with clopidogrel, but an
increased bleeding complications. The large scale, long-term, ran-
domized trials should be needed to assess the safety of P2Y12 RI for
Korean AMI patients undergoing successful PCI.TCTAP A-023
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BACKGROUND Introduction- The response to Clopidogrel, a pro-drug
requiring CYP450 biotransformation is not uniform. Data suggest its
pharmacologic effect varies based on CYP2C19 genotype, but there is
uncertainty regarding the clinical impact of platelet function test and
genotyping.
Objectivedin this study on patients with coronary artery disease
treated with percutaneous coronary intervention (PCI), we evaluated
the clinical impact of platelet reactivity measured by platelet function
test and gene polymorphism assessed by genotyping in Korean
patients.
METHODS A Database search 0f Chungbuk Regional cardiovascular
center was conducted (January 2010-August 2014). Platelet function
test and genetic studies were included where clopidogrel was initiated
in conventional PCI in the ischemic heart disease.
RESULTS A total of 567 patients with coronary artery disease treated
by PCI were enrolled. The level of P2Y12 reaction unit (PRU) of the
patients with CYP*2 or*3 heterozygote or CYP*2/*2 or *2/*3 or *3/*3
was signiﬁcantly higher than with CYP*1/*1 or *1/*17(20986.8
(extensive metabolizers, EMs) vs. 22887.1 (intermediate metabo-
lizers, IMs) vs. 24384.4 (poor metabolizers, PMs), p ¼0.006, 1 way
ANOBA). The frequency of high on-treatment clopidogrel platelet
reactivity (HPR) was also signiﬁcantly higher in IMs and PMs (p ¼
0.002). At1-year follow-up, the major cardiac adverse event occurred
more frequently inpatients with high on-treatment clopidogrel
platelet reactivity compared with patients without high on-treatment
clopidogrel platelet reactivity, when platelet function was evaluated
with the Verify Now P2Y12 assay (23 (9.3%) vs. 27 (7.5%), p¼0.27)
without statistical signiﬁcance. Kaplan-Meier test for MACE-free
survival did not showed signiﬁcant difference in survival analysis
between High on-treatment clopidogrel platelet reactivity and non-
High on-treatment clopidogrel platelet reactivity group. At 1-year
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was similar between the patients with extensive metabolizers and
with poor and intermediate metabolizers (19 (9.5%) vs. 21 (8.4%),
p¼0.73). Survival analysis revealed similar MACE rates in patients
with poor and intermediate metabolizers with respect to extensive
metabolizers.
CONCLUSION Among Korean patients treated with clopidogrel for
PCI, carriage of even one reduced function CYP2C19 allele appears to
be associated signiﬁcantly with an increased level of PRU and a higher
incidence of High on-treatment clopidogrel platelet reactivity but
both the platelet reactivity and gene polymorphisms did not predict
major adverse cardiovascular events.TCTAP A-024
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BACKGROUND The dual antiplatelet therapy (DAPT) including aspirin
and clopidogrel is the standard therapy in percutaneous coronary
intervention (PCI).However, the divergent duration of DAPT and the
varying response of clopidogrel were two substantial concerns in the
era of PCI, especially with drug-eluting stents (DES) implantation.
Therefore, we combined them together to evaluate their effect on long
term inﬂuence on patients undergoing DES.
METHODS Patients with coronary artery disease treated exclusively
with Cypher sirolimus-eluting stents (SES) or Endeavor zotarolimus-
eluting stents (ZES) between September 2006 and June 2009 were
screened. Among them patients were eligible for participation in this
retrospective analysis if they had undergone PCI implantation since
enrollment and not had a major adverse cardiovascular event (death,
myocardial infarction, stroke, stent thrombosis or repeat revasculari-
zation) within the ﬁrst year since implantation. all patients were
routinely measured AA and ADP during the PCI procedure. And then
all of the procedures were performed using standard interventional
techniques. The interventional strategy and device utilization,
including DES type (SES or ZES), were left to the discretion of the
operators. The primary endpoint (MACCE) was a composite of all-
cause death, nonfatal myocardial infarction (MI), stent thrombosis,
unexpected repeat revascularization, and stroke.
RESULTS 1245 suitable patients were analyzed for our purpose. There
were 204, 419, 289, 333 patients in the A group (12 month DAPT & low
platelet aggregation), B group (>12 month DAPT & high platelet ag-
gregation), C group (12 month DAPT & high platelet aggregation), D
group (>12 month DAPT & low platelet aggregation), respectively.
Compared with the rest of patients, the D group was associated with
decreased incidence of MACCE [HR 0.485, 95%CI (0.25-0.96);
P¼0.038]; when cox proportional hazard models were further tested
with the D group as the reference category within the same group, the
B and C group were associated with more incidence of MACCE[HR
2.26, 95%CI (1.10-4.68); P¼0.0273] and [HR 2.31, 95%CI (1.03-
5.18);P¼0.0413]. Their respective multivariate Cox proportional
hazards regressions conﬁrmed the tendencies mentioned above. As
concerned to MACE, The univariate Cox proportional hazards
regression demonstrated the B group, overlapping stents, small ves-
sels, and PVD were also linked to more incidence of MACE. After
adjustment by multivariate Cox proportional hazards regression, PVD
was still an independent risk factor of the MACCE.
CONCLUSION This is the ﬁrst study that took into account the
duration of DAPT and serial measurement of individual platelet
function together in the routine clinical practice in the long term.
The present study demonstrated the lower mean ADP level could
guarantee a clinical beneﬁt in the long term not only in primary
endpoint but also in secondary endpoint. This relationship suggested
the mean of ADP could better reﬂect the response of clopidogrel and
underlined the importance of serial measurements of ADP in chronic
administration. Our study demonstrated serial measurement of ADP
level was of importance in long term use of DAPT; The present re-
sults demonstrated patients with extension of DAPT above a year
with lower ADP level could beneﬁt compared with the rest patients.
Further comparisons were made among the four groups, which
suggested the B and C groups were risk factors compared with the D
group. In other words, it supported the D group was superior to the
B and C groups.TCTAP A-025
Impact for Discontinuation of Dual Antiplatelet Therapy for Unexpected
Reason Within 3 Months After 2nd Drug Eluting Stent Implantation
Yohsuke Honda1
1Saiseikai Yokohama City Eastern Hospital, Japan
BACKGROUND To assess the safety of discontinuation of dual anti-
platelet therapy (DAPT) for unexpected reason within 3 months
after2nd drug-eluting-tent (2nd DES) implantation.
METHODS A total of 1661 consecutive patients(age 7010 years, male
74%)(2764 lesions) who underwent 2nd DES implantation was
enrolled. 150 patients (190 lesions) received DAPT within 3 months
(short group) and 1577 patients (2526 lesions) received DAPT above
3months (long group). 34 patients (48 lesions) who stopped both of
antiplatelet therapy excluded. The typical reasons to stop DAPT
within 3months were allergy, bleeding and no adherence. Primary
outcome was deﬁnite and probable stent thrombosis deﬁned by Aca-
demic Research Consortium (ARC).
RESULTS Patient and lesion characteristics were similar between two
groups except age which was higher in short group than long group
(7210 vs. 6910, p＜0.001). Mean DAPT duration was 3633 days in
short group and 698386 days in long group. Aspirin was mainly
selected as whole life single antiplatelet therapy in both groups (short
82.4% vs. long 81.7%, p¼0.82). In follow up term (24.713.4 months),
the incidence of ST was similar between two groups (1.0% in short
group vs. 0.5% in long group, p¼0.34).
CONCLUSION Discontinuation of DAPT for unexpected reason within
3 months after 2nd DES implantation did not increase the risk for ST.
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BACKGROUND Warfarin, an anticoagulant drug has been used regu-
larly despite of its bleeding tendency. This adverse effect is usually
controlled by checking International Normalized Ratio (INR). The aim
of this study is to determine the ability of plasma metabolites to
distinguish individuals with different INR stability.
METHODS This study focuses on two types of patients; stable INR
(2-3) and unstable INR (<2 or >3), 44 patients of stable group, and 50
patients of unstable group, on at least 9-month warfarin treatment.
Both groups were selected based on Morisky scale> 6 (medium to high
adherence). The INR was monitored for each individual during the last
six months of the treatment period. INR case without changes was
considered stable. Otherwise, it would be considered unstable. The
blood samples were centrifuged and the obtained plasma samples
were mixed with phosphate buffer (1:1). The mixture was centrifuged
and the supernatant was taken to perform 1H-NMR experiment. The
NMR spectra were binned and the data were analyzed using principle
component analysis (PCA) and orthogonal partial least squares
discriminant analysis (OPLS-DA).
RESULTS Fifteen female and 29 male patients (mean age 66.5),
treated with the average warfarin dose of 3.08 mg, showed a stable
INR while the unstable group including 28 males and 22 females
(mean age 64.7) was treated with the average dose of 3.66 mg. No
signiﬁcant difference was observed between two groups with respect
to warfarin dose (p¼ 0.066), the patient age (p¼ 0.415) and gender
(p¼ 0.332). Three outliers were identiﬁed in PCA score plot. The OPLS-
DA four-component model (96% accuracy, 97.73% sensitivity, and
96.81% speciﬁcity) with R2 (cum) ¼ 0.575 and Q2 (cum) ¼ 0.355
revealed a clear separation between the two groups. Through the VIP
plot, the discriminatory metabolites were determined.
CONCLUSION The plasma metabolomics technique able to differen-
tiate the plasma metabolic proﬁles of the patients on warfarin with
stable and unstable INR. Validations of the metabolites with more
subjects are ongoing.
